


Synthistat

Multi-target HDAC drugs for resistant blood cancers, with a commercial enhancer program alongside.

PRE-SEED · SEIS/EIS · £250,000 · JUNE 2026

Private and confidential - do not distribute

PROBLEM

Resistant AML: Unmet Need, Stalled Drugs, Open Chemistry

1

Unmet Need Persists

AML 5-year survival remains poor. Venetoclax + HMA improved outcomes, but resistance and relapse dominate.

2

Single-Target HDACi Has Stalled

Big pharma scaled back after vorinostat and panobinostat. Multi-target HDAC + BRD4/PARP1/D2R largely unexplored.

3

Chemistry Space Is Uncrowded

Academic programmes at MD Anderson and Dana-Farber. No company-level HDAC/D2R/PARP1 inhibitor architecture identified.



PROBLEM

Gene therapy's supply crisis is costing lives by limiting patient access

Yield = Cost = Lives

Per-batch LVV titre sets cost per dose. Cost gates access — every yield gain compounds across every patient reached.

Weak IP

Sodium butyrate and proprietary mixes rely on trade secrecy — not composition-of-matter patents.

SOLUTION

Two Programmes, One Platform

Capital-efficient by design — same chemistry supports a long-horizon oncology pipeline and a near-term commercial derisking business.

Lead Programme

Dual- & multi-target HDAC drugs

- HDAC + BRD4 / PARP1 / D2R inhibitor architectures
- Lead indication: resistant AML
- Provisional patents filed
- Out-licence path: GSK, Ellipses Pharma in conversation
- HDAC licensing commands major deals — e.g. Novartis / Chong Kun Dang, ~$1.3B (2023)

Commercial Programme · Derisking

Lentiviral vector enhancers

- HDACi chemistry repurposed for LVV production
- Mechanism validated — Abdi et al. 2025
- Compound evaluation invited by Cytiva.
- Comparable exit: Merck KGaA / Mirus Bio, 2024

SOLUTION

Next generation multi targeting epigenetic regulators

Dual-Mechanism Epigenetic Inhibitors


Select HDAC inhibitors exhibit multi antagonism of HDAC isoforms, PARP1, D2R or BRD4, enabling targeting of both epigenetic regulation and survival or transcriptional pathways in AML and solid cancers.


Drug-Like Optimisation

Lead compounds demonstrate favourable physicochemical and ADME characteristics, outperforming benchmark HDAC inhibitors including panobinostat.

Potent Multi-Target Engagement

Predicted nanomolar potency across HDAC2/6 and D2R or BRD4 supports differentiated single-agent activity.





Two Different Answers

Oncology Programme

They tried single-target. Not multi-target.

- HDACi category reduced after vorinostat/panobinostat clinical winter
- Dual-mechanism programmes exist at MD Anderson, Dana-Farber — not at company level
- HDAC/D2R/PARP1 inhibitor architecture is uncrowded

Enhancer Programme

Wrong business for big pharma

- Buyers are tools suppliers — Thermo Fisher, Cytiva, Sartorius, Merck KGaA
- Mirus Bio built this; acquired by Merck KGaA tools division — not pharma
- Big pharma has no incentive to develop reagents they don't sell

COMPETITIVE LANDSCAPE

Synthistat vs. Key Incumbents

DIMENSION	HDAC-ONLY BENCHMARK	SYNTHISTAT (HDAC + BRD4)	INVESTOR RELEVANCE
Target Engagement	HDAC inhibition only	Dual HDAC2/6 + BRD4 engagement	Simultaneous epigenetic and transcriptional modulation
Predicted Activity	HDAC2 binding (~8.5 kcal/mol)	HDAC2 binding (~8.5 kcal/mol) with additional BRD4 engagement	Potential multi-pathway efficacy from a single molecule
Mechanistic Profile	Single-target epigenetic regulation	Dual inhibition of epigenetic writers/readers and transcriptional drivers	Differentiated biological mechanism
Development Potential	Established therapeutic class	Expanded target coverage and indication flexibility	Potential for broader clinical positioning
Strategic Value	Conventional HDAC inhibitor profile	Differentiated dual-target epigenetic asset	Enhanced partnering and licensing attractiveness
Market Opportunity	Broad oncology applications	MYC-driven and transcription-dependent malignancies	Large addressable oncology market

POTENTIAL STRATEGIC DIFFERENTIATION


HDAC-only assets
Established epigenetic therapies

Synthistat dual-action assets
Dual HDAC/BRD4 targeting with expanded biological scope

OUTCOME
- Broader mechanism
- Differentiated positioning
- Potentially enhanced partnering value

MARKET

A multi-billion-dollar oncology opportunity



Sizing Logic

- TAM represents the global oncology therapeutics market
- SAM focuses on epigenetic oncology therapies, including HDAC, BET/BRD4, PARP and combination approaches
- SOM reflects initial target indications with high unmet need, including AML, TNBC, SCLC and MYC-driven cancers

Detailed indication-level market model and valuation assumptions available in the data room.

TRACTION

Validated mechanism. Pilot data. A direct ask from Cytiva.

Published Mechanism Validation

Abdi et al. 2025, *Cytotherapy** — ISCT 2025 podium + poster.

In-House Pilot Data

2–3× LVV titre uplift vs LV-MAX baseline (n = 5).

Direct Industry Signal

Cytiva (Danaher) invited Synthistat to submit HDACi compounds for in-house testing.

IP Estate

Provisional patent families filed; PCT conversion funded by this raise.

*Abdi, Zakeria. (2025). Panobinostat for Improved LVV Production Versus Other HDAC Inhibitors. Cytotherapy. 27. S37. 10.1016/j.jcyt.2025.03.060.

BUSINESS MODEL

Three revenue paths — staged by time to cash

Enhancer Reagent & Kit Revenue

Near-Term 12–24 Months

Enhancer reagent & kit sales to CDMOs. **≥80% gross margin.**

Technology Licensing & Partnership

Medium-Term 24–48 Months

Technology licensing to Cytiva, Sartorius, Thermo Fisher. **5-10% recurring licensing fees**.

Oncology Out-License

Longer-Term 36+ Months

Oncology out-licence at IND-enabling stage. Up-front + milestone + royalty. Potential partners: **GSK, Ellipses Pharma.**

Mirus Bio comparable: Merck KGaA paid ~$600M (2024) for a focused viral-vector transfection reagents specialist.

GO TO MARKET

Three routes to first customers

Direct Technical Engagement

Sample-and-evaluate route to commercial terms.
Active: Cytiva
Verbal: Sartorius, Mirus Bio.

Ecosystem Distribution

Stevenage Bioscience Catalyst* gives direct reach into the UK/EU cell-and-gene cluster and same site proximity to GSK

Academic & CDMO Partnerships

University of Freiburg partnership opens translational research and joint IP; CDMO accounts anchor sales.

*Stevenage Bioscience Catalyst a science campus 20 minutes north of London. Home to major organisations including GSK, the Cell and Gene Therapy Manufacturing Catapult, LifeArc and Cytiva alongside a growing cluster of over 45 start-up companies

COMPETITION & MOAT

Proprietary chemistry, not trade secret

	Thermo Fisher LV-MAX	Mirus Bio	Generic Sodium Butyrate	Synthistat
IP Basis	Trade secret	Trade secret	None	Composition of matter
Performance	Industry standard	Industry standard	Variable	Designed to exceed
Patent Protection	Limited	Limited	None	Strong, defensible
Applications	Single use	Single use	Single use	Enhancer + oncology

The window is open: incumbents rely on trade secrets, while Synthistat is building proprietary composition-of-matter IP enhancer chemistry. It will not stay open indefinitely.

TEAM

Founder-led science with industry-credible advisors.



CEO

Zakeria Abdi

Hands-on experience with HDAC chemistry, LVV production, and computational compound design. Leads experimental design, synthesis strategy, and platform direction. First author, Abdi et al. 2025



Chairman

Arfan Afzal

Founder & MD, Capital Blossom Ltd. 20+ years across UK, Saudi Arabia, UAE, and Oman. Regional advisor on the Saudi FDA approval of ArtemiC for MGC Pharmaceuticals



Senior Scientific Advisor

Dr George Okafo

30+ years pharma R&D. Global roles at Boehringer Ingelheim, GSK, Insilico Medicine. Data strategy advisor. Board Trustee, Society of Chemical Industry. PhD Imperial College; 60+ publications.



Head of Investor Relations


Zak Mir

30+ years in UK capital markets. Derivatives broker at Sucden, Union Cal (Man Group), and Berkeley Futures. Founded Miriad (financial PR) and Lift Global Ventures, an Aquis-listed fintech investment company; CEO for four years.

Execution Capacity: Enamine (medicinal chemistry CRO) · University of Freiburg (compound synthesis) · Stevenage Bioscience Catalyst (lab infrastructure)

ROADMAP

Provisional IP and pilot data today → institutional Seed in 12–18 months



Key value inflection by Q2 2027: validated enhancer leads · PCT conversion · Preliminary in-house oncology efficacy data · Cytiva evaluation result.

THE ASK

£250,000 · SEIS/EIS-eligible · 18 months runway

Round Terms

£250,000
Round size

£1.25M
Pre-money valuation

- SEIS/EIS-eligible ordinary shares
- 50% income tax relief (SEIS) / 30% (EIS)
- CGT exemption

Use of Funds

- £105k — Salaries & operations
- £82.5k — Research & services (Enamine synthesis, in vitro oncology, LVV experiments)
- £45k — IP & legal (PCT conversion, patent drafting)
- £17.5k — Lab rental (Stevenage Bioscience Catalyst)

EXIT PATHWAY

Strategic buyers are active in oncology and viral-vector tools

Acquisition Comparables

- Merck KGaA/Mirus Bio: **~$600M (2024)**
- Thermo/Brammer : **$1.7B at ~6.8× revenue (2019)**
- Danaher/Aldevron: **$9.6B (2021)**
- Novartis / Chong Kun Dang, ~**$1.3B (2023)**
- Strategic acquirers pay premium multiples for proprietary, hard-to-replicate tools.
- Out-licence path: GSK, Ellipses Pharma in conversation

Plausible Buyers

- Danaher / Cytiva — compound evaluation invited
- Thermo Fisher — LV-MAX owner
- Merck KGaA — already acquired in category
- Sartorius — verbal interest at Pioneer events
- GSK — connected via SBC ecosystem
- Ellipses – business development group

Synthistat targets the same strategic buyer pool with patent-pending enhancer chemistry, not trade-secret incumbency

RETURN LOGIC

A low entry valuation ahead of defined value inflection points

Today

£1.25M pre-money

- Provisional IP
- Pilot data
- SBC subsidized lab space
- Cytiva evaluation request

12-18 Months

~£10M Seed target

- Validated enhancer leads
- PCT conversion
- Cytiva evaluation result
- Preliminary oncology data set

Potential Uplift

~8× valuation step-up

- Driven by technical validation
- IP progression
- Strategic buyer relevance



Supporting Novel Treatments and CGT Manufacturing

Why Now?

- Pilot data showing **2–3× LVV titre uplift.**
- **Patent-pending** platform chemistry for oncology and LVV enhancers.
- **Cytiva evaluation underway.**
- Key value-inflection milestones within 18 months
- SBC ecosystem integration and partnerships taking shape

Invest before patent conversion, strategic validation and first oncology data

£250,000 Pre-Seed Open - SEIS/EIS Eligible

Contact: info@synthistat.com

Request the data room under NDA

Information only; not an offer of securities or investment advice. Forward-looking statements and projections — including market sizes, valuations, timelines and milestones — are illustrative targets, not guarantees, and actual outcomes may differ materially. SEIS/EIS relief depends on individual circumstances and continued qualifying status.